The significance of DNA mismatch repair genes in the diagnosis and management of periocular sebaceous cell carcinoma and Muir-Torre syndrome

British Journal of Ophthalmology

Volumn 95, Issue 12, 2011, Pages 1686-1690

  Gaskin, Brent J ^a   Fernando, Bertie S ^a   Sullivan, Charlotte A ^a   Whitehead, Kevin ^b   Sullivan, Timothy J ^a,c  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b SULLIVAN NICOLAIDES PATHOLOGY   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MISMATCH REPAIR PROTEIN; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA MISMATCH REPAIR GENE; ESSENTIAL GENE; EYELID CARCINOMA; FEMALE; GENE FUNCTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOWER EYELID; MALE; METASTASIS; MISMATCH REPAIR; MUIR TORRE SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEBACEOUS CARCINOMA; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; DNA MISMATCH REPAIR; DNA, NEOPLASM; EYELID NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEDICAL RECORDS; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; MIDDLE AGED; MUIR-TORRE SYNDROME; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 81555214106     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2011-300612     Document Type: Article

References (33)

1. Lazar AJ, Lyle S, Calonje E. Sebaceous neoplasia and Torre-Muir syndrome. Curr Diagn Pathol 2007;13:301-19. (Pubitemid 47285724)
2. Wolfe JT 3rd, Yeatts RP, Wick MR, et al. Sebaceous carcinoma of the eyelid. Errors in clinical and pathologic diagnosis. Am J Surg Pathol 1984;8:597-606. (Pubitemid 14055018)
3. Rao NA, Hidayat AA, McLean IW, et al. Sebaceous carcinomas of the ocular adnexa: a clinicopathologic study of 104 cases, with five-year follow-up data. Hum Pathol 1982;13:113-22. (Pubitemid 12131097)
4. Ni C, Searl SS, Kuo PK, et al. Sebaceous cell carcinomas of the ocular adnexa. Int Ophthalmol Clin 1982;22:23-61.
5. Ni C, Guo BK. Pathologic classification of meibomian gland carcinomas of eyelids: clinical and pathologic study of 156 cases. Chin Med J (Engl) 1979;92:671-6. (Pubitemid 10218141)
6. Boniuk M, Zimmerman LE. Sebaceous carcinoma of the eyelid, eyebrow, caruncle, and orbit. Trans Am Acad Ophthalmol Otolaryngol 1968;72:619-42.
7. Muir EG, Bell AJ, Barlow KA. Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face. Br J Surg 1967;54:191-5.
8. Torre D. Multiple sebaceous tumors. Arch Dermatol 1968;98:549-51.
9. Ponti G, Losi L, Di Gregorio C, et al. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry. Cancer 2005;103:1018-25. (Pubitemid 40270079)
10. Alessi E, Brambilla L, Luporini G, et al. Multiple sebaceous tumors and carcinomas of the colon: Torre syndrome. Cancer 1985;55:2566-74. (Pubitemid 15092141)
11. Graham R, Mckee P, Mcgibbon D, et al. TorreeMuir syndrome. An association with isolated sebaceous carcinoma. Cancer 1985;55:2868-73. (Pubitemid 15008331)
12. Shields JA, Demirci H, Marr BP, et al. Sebaceous carcinoma of the eyelids. Personal experience with 60 cases. Ophthalmology 2004;111:2151-7. (Pubitemid 39575582)
13. Kass LG, Hornblass A. Sebaceous carcinoma of the ocular adnexa. Surv Ophthalmol 1989;33:477-90. (Pubitemid 19146364)
14. Doxanas MT, Green WR. Sebaceous gland carcinoma. Review of 40 cases. Arch Ophthalmol 1984;102:245-9. (Pubitemid 14184162)
15. Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. Cancer 2009;115:158-65.
16. Ginsberg J. Present status of meibomian gland carcinoma. Arch Ophthalmol 1965;73:271-7.
17. Harvey JT, Anderson RL. The management of meibomian gland carcinoma. Ophthalmic Surg 1982;13:56-61. (Pubitemid 12137411)
18. Epstein GA, Putterman AM. Sebaceous adenocarcinoma of the eyelid. Ophthalmic Surg 1983;14:935-40. (Pubitemid 14249171)
19. Zürcher M, Hintschich CR, Garner A, et al. Sebaceous carcinoma of the eyelid: a clinicopathological study. Br J Ophthalmol 1998;82:1049-55. (Pubitemid 28451278)
20. Song A, Carter KD, Syed NA, et al. Sebaceous cell carcinoma of the ocular adnexa: clinical presentations, histopathology, and outcomes. Ophthal Plast Reconstr Surg 2008;24:194-200.
21. Cohen PR, Kohn SR, Kurzrock R. Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. Am J Med 1991;90:606-13.
22. Ponti G, Ponz de Leon M. Muir-Torre syndrome. Lancet Oncol 2005;6:980-7. (Pubitemid 41685231)
23. Kruse R, Ruzicka T. DNA mismatch repair and the significance of a sebaceous skin tumor for visceral cancer prevention. Trends Mol Med 2004;10:136-41. (Pubitemid 38293350)
24. Entius MM, Keller JJ, Drillenburg P, et al. Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome. Clin Cancer Res 2000;6:1784-9. (Pubitemid 30305072)
25. Esche C, Kruse R, Lamberti C, et al. Muir-Torre syndrome: clinical features and molecular genetic analysis. Br J Dermatol 1997;136:913-17. (Pubitemid 27283524)
26. Honchel R, Halling KC, Schaid DJ, et al. Microsatellite instability in Muir-Torre syndrome. Cancer Res 1994;54:1159-63. (Pubitemid 24108050)
27. Peris K, Onorati MT, Keller G, et al. Widespread microsatellite instability in sebaceous tumours of patients with the Muir-Torre syndrome. Br J Dermatol 1997;137:356-60. (Pubitemid 27421560)
28. Mathiak M, Rutten A, Mangold E, et al. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test. Am J Surg Pathol 2002;26:338-43. (Pubitemid 34184457)
29. Orta L, Klimstra DS, Qin J, et al. Towards identification of hereditary DNA mismatch repair deficiency: sebaceous neoplasm warrants routine immunohistochemical screening regardless of patient's age or other clinical characteristics. Am J Surg Pathol 2009;33:934-44.
30. Chhibber V, Dresser K, Mahalingam M. MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome. Mod Pathol 2008;21:159.
31. Goldberg M, Rummelt C, Foja S, et al. Different genetic pathways in the development of periocular sebaceous gland carcinomas in presumptive Muir-Torre syndrome patients. Hum Mutat 2006;27:155-62. (Pubitemid 43238031)
32. Jayaraj P, Sen S, Kashyap S, et al. Does β-catenin have a role in pathogenesis of sebaceous cell carcinoma of the eyelid? Br J Ophthalmol 2011;95:284-7.
33. Dores GM, Curtis RE, Toro JR, et al. Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms insight into Muir-Torre syndrome. Cancer 2008;113:3372-81.